Intrathecal baclofen for spasticity
Villanueva E, Anderson J
Record ID 32003000664
This aim of this report was to assess whether intrathecal baclofen is beneficial in hereditary spastic paraplegia.
Authors' recomendations: - One systematic review published in 1997 was retrieved. We found no studies on this topic published since 1997. - The review examined the effectiveness of intrathecal baclofen on general severe spasticity. High-level evidence for hereditary spastic paraplegia is lacking. - Data from 27 studies representing the experience of 490 patients is examined. - Primary endpoints include changes in Ashworth and Penn scores, duration of follow-up, and dosage at last follow-up - Mean Ashworth scores decreased from 3.9 to 1.6 (p<0.001) - Mean Penn scores decreased from 3.5 to 0.7 (p<0.001) - Cumulative success of 78.1% was reported - Over 16 months, dosage increased by an average of 250% from baseline.
Authors' methods: Review
Project Status: Completed
URL for project: http://www.med.monash.edu.au/healthservices/cce/evidence/
Year Published: 2000
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Spastic Paraplegia, Hereditary
Organisation Name: Centre for Clinical Effectiveness
Contact Address: Monash Institute of Health Services Research, Block E, Monash Medical Centre, Locked Bag 29, Clayton, Victoria 3168, Australia. Tel: +61 3 9594 7505; Fax: +61 3 9594 7552.
Contact Name: email@example.com.
Contact Email: firstname.lastname@example.org.
Copyright: Centre for Clinical Effectiveness (CCE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.